

# Tsuyoshi Saitoh

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/529023/publications.pdf>

Version: 2024-02-01

114  
papers

2,686  
citations

257450

24  
h-index

223800

46  
g-index

121  
all docs

121  
docs citations

121  
times ranked

2409  
citing authors

#	ARTICLE	IF	CITATIONS
1	Dynorphin Acts as a Neuromodulator to Inhibit Itch in the Dorsal Horn of the Spinal Cord. <i>Neuron</i> , 2014, 82, 573-586.	8.1	290
2	In silico design of novel probes for the atypical opioid receptor MRGPRX2. <i>Nature Chemical Biology</i> , 2017, 13, 529-536.	8.0	230
3	Discovery of a Structurally Novel Opioid $\kappa$ -Agonist Derived from 4,5-Epoxymorphinan.. <i>Chemical and Pharmaceutical Bulletin</i> , 1998, 46, 366-369.	1.3	167
4	Nonpeptide orexin type-2 receptor agonist ameliorates narcolepsy-cataplexy symptoms in mouse models. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2017, 114, 5731-5736.	7.1	107
5	Anodic Oxidation on a Boron-Doped Diamond Electrode Mediated by Methoxy Radicals. <i>Angewandte Chemie - International Edition</i> , 2012, 51, 5443-5446.	13.8	95
6	Design and Synthesis of Non-Peptide, Selective Orexin Receptor 2 Agonists. <i>Journal of Medicinal Chemistry</i> , 2015, 58, 7931-7937.	6.4	90
7	Rational Drug Design and Synthesis of a Highly Selective Nonpeptide $\delta$ -Opioid Agonist, (4aS*,12aR*)-4a-(3-Hydroxyphenyl)-2-methyl-1,2,3,4,4a,5,12,12a-octahydropyrido[3,4-b]acridine (TAN-67).. <i>Chemical and Pharmaceutical Bulletin</i> , 1998, 46, 1695-1702.	1.3	74
8	Design, synthesis, and structure-activity relationship of novel opioid $\mu$ -agonists. <i>Bioorganic and Medicinal Chemistry</i> , 2008, 16, 9188-9201.	3.0	73
9	Large-scale forward genetics screening identifies <i>Trpa1</i> as a chemosensor for predator odor-evoked innate fear behaviors. <i>Nature Communications</i> , 2018, 9, 2041.	12.8	71
10	Design and synthesis of KNT-127, a $\mu$ -opioid receptor agonist effective by systemic administration. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2010, 20, 6302-6305.	2.2	66
11	Antinociceptive effects of the selective non-peptidic $\mu$ -opioid receptor agonist TAN-67 in diabetic mice. <i>European Journal of Pharmacology</i> , 1995, 276, 131-135.	3.5	58
12	Opioids in Preclinical and Clinical Trials. <i>Topics in Current Chemistry</i> , 2010, 299, 29-62.	4.0	57
13	The pharmacological profile of $\mu$ opioid receptor ligands, (+) and ( $\Delta^7$ ) TAN-67 on pain modulation. <i>Life Sciences</i> , 2001, 68, 2227-2231.	4.3	46
14	A solvent-directed stereoselective and electrocatalytic synthesis of diisoeugenol. <i>Chemical Communications</i> , 2018, 54, 2771-2773.	4.1	41
15	Application of Electrochemically Generated Hypervalent Iodine Oxidant to Natural Products Synthesis. <i>Electrochemistry</i> , 2013, 81, 319-324.	1.4	40
16	Design and synthesis of novel delta opioid receptor agonists and their pharmacologies. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2009, 19, 2792-2795.	2.2	39
17	Effects of a highly selective nonpeptide $\mu$ opioid receptor agonist, TAN-67, on morphine-induced antinociception in mice. <i>Life Sciences</i> , 1995, 57, 155-168.	4.3	38
18	Drug design and synthesis of a novel $\mu$ opioid receptor agonist with an oxabicyclo[2.2.2]octane skeleton and its pharmacology. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2010, 20, 121-124.	2.2	33

#	ARTICLE	IF	CITATIONS
19	Design and Synthesis of Potent and Highly Selective Orexin 1 Receptor Antagonists with a Morphinan Skeleton and Their Pharmacologies. <i>Journal of Medicinal Chemistry</i> , 2017, 60, 1018-1040.	6.4	30
20	Enhancing endogenous adenosine A2A receptor signaling induces slow-wave sleep without affecting body temperature and cardiovascular function. <i>Neuropharmacology</i> , 2019, 144, 122-132.	4.1	30
21	Synthesis of a Stable Iminium Salt and Propellane Derivatives. <i>Journal of Organic Chemistry</i> , 2008, 73, 8093-8096.	3.2	27
22	The facility of formation of a .DELTA.6 bond in dihydromorphinone and related opiates. <i>Journal of Organic Chemistry</i> , 1989, 54, 4120-4125.	3.2	26
23	Synthesis of Firefly Luciferin Analogues and Evaluation of the Luminescent Properties. <i>Chemistry - A European Journal</i> , 2016, 22, 9330-9337.	3.3	26
24	Oxidative Cyclization Reactions of Tryptamine Utilizing Hypervalent Iodobenzene in Routes for Pyrroloindole Alkaloid Synthesis. <i>Synthesis</i> , 2012, 44, 1667-1671.	2.3	24
25	Research and development of $\mu$ opioid receptor agonists and $\kappa$ opioid receptor agonists. , 2020, 205, 107427.		24
26	Novel Synthesis of a 1,3,5-Trioxazatriquinane Skeleton Using a Nitrogen Clamp. <i>Organic Letters</i> , 2009, 11, 539-542.	4.6	23
27	Cerebral capillary blood flow upsurge during REM sleep is mediated by A2a receptors. <i>Cell Reports</i> , 2021, 36, 109558.	6.4	23
28	Essential Structure of the $\mu$ Opioid Receptor Agonist Nalfurafine for Binding to the $\mu$ Receptor. <i>Current Pharmaceutical Design</i> , 2014, 19, 7400-7414.	1.9	23
29	Nonpeptide Orexin-2 Receptor Agonist Attenuates Morphine-induced Sedative Effects in Rats. <i>Anesthesiology</i> , 2018, 128, 992-1003.	2.5	22
30	Peripheral Opioid Antagonist Enhances the Effect of Anti-Tumor Drug by Blocking a Cell Growth-Suppressive Pathway In Vivo. <i>PLoS ONE</i> , 2015, 10, e0123407.	2.5	21
31	Electrochemical Pinacol Coupling of Acetophenone Using Boron-Doped Diamond Electrode. <i>ChemElectroChem</i> , 2019, 6, 4153-4157.	3.4	21
32	Toward bioluminescence in the near-infrared region: Tuning the emission wavelength of firefly luciferin analogues by allyl substitution. <i>Tetrahedron Letters</i> , 2018, 59, 1087-1090.	1.4	20
33	Efficient synthesis of ( $\Delta^7$ )-parasitenone, a novel inhibitor of NF- $\kappa$ B. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2009, 19, 5383-5386.	2.2	19
34	Synthesis of Novel Basic Skeletons Derived from Naltrexone. <i>Topics in Current Chemistry</i> , 2010, 299, 187-237.	4.0	19
35	Essential structure of opioid $\mu$ receptor agonist nalfurafine for binding to the $\mu$ receptor 2: Synthesis of decahydro(iminoethano)phenanthrene derivatives and their pharmacologies. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2012, 22, 5071-5074.	2.2	19
36	Controlled decoration of boron-doped diamond electrodes by electrochemical click reaction (e <sup>-</sup> CLICK). <i>Carbon</i> , 2018, 130, 350-354.	10.3	18

#	ARTICLE	IF	CITATIONS
37	Effects of repeated treatment with a delta opioid receptor agonist KNT-127 on hyperemotionality in olfactory-bulbectomized rats. <i>Behavioural Brain Research</i> , 2017, 323, 11-14.	2.2	17
38	The delta opioid receptor agonist KNT-127 in the prelimbic medial prefrontal cortex attenuates veratrine-induced anxiety-like behaviors in mice. <i>Behavioural Brain Research</i> , 2018, 336, 77-84.	2.2	17
39	DOR2-selective but not DOR1-selective antagonist abolishes anxiolytic-like effects of the $\mu$ opioid receptor agonist KNT-127. <i>Neuropharmacology</i> , 2014, 79, 314-320.	4.1	16
40	Design and synthesis of quinolinopropellane derivatives with selective $\mu$ opioid receptor agonism. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2014, 24, 2851-2854.	2.2	16
41	Naltrindole derivatives with fluorinated ethyl substituents on the 17-nitrogen as $\mu$ opioid receptor inverse agonists. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2015, 25, 2927-2930.	2.2	16
42	Essential Structure of Opioid $\mu$ Receptor Agonist Nalfurafine for Binding to $\mu$ Receptor 1: Synthesis of Decahydroisoquinoline Derivatives and Their Pharmacologies. <i>Chemical and Pharmaceutical Bulletin</i> , 2012, 60, 945-948.	1.3	15
43	Determination of topological structure of ARL6ip1 in cells: Identification of the essential binding region of ARL6ip1 for conophylline. <i>FEBS Letters</i> , 2013, 587, 3656-3660.	2.8	15
44	Synthesis of (+)-Methylthalibrine by Employing a Stereocontrolled Bischler-Napieralski Reaction and an Electrochemically Generated Diaryl Ether. <i>European Journal of Organic Chemistry</i> , 2014, 2014, 99-104.	2.4	15
45	Modulation of glutamatergic synaptic transmission and neuronal excitability in the prelimbic medial prefrontal cortex via delta-opioid receptors in mice. <i>Biochemical and Biophysical Research Communications</i> , 2021, 560, 192-198.	2.1	15
46	A Double Decarboxylation Reaction of an Oxazolidinone and Carboxylic Acid: Its Application to the Synthesis of a New Opioid Lead Compound. <i>Journal of Organic Chemistry</i> , 2010, 75, 995-998.	3.2	14
47	Opioid $\mu$ 1 receptor antagonist 7-benzylidenenaltrexone as an effective resistance reverser for chloroquine-resistant <i>Plasmodium chabaudi</i> . <i>Bioorganic and Medicinal Chemistry Letters</i> , 2011, 21, 4710-4712.	2.2	14
48	Investigation of 7-benzylidenenaltrexone derivatives as resistance reverser for chloroquine-resistant <i>Plasmodium chabaudi</i> . <i>Bioorganic and Medicinal Chemistry Letters</i> , 2012, 22, 5174-5176.	2.2	14
49	Synthesis and Pharmacology of a Novel $\mu$ Opioid Receptor (KOR) Agonist with a 1,3,5-Trioxazatriquinane Skeleton. <i>ACS Medicinal Chemistry Letters</i> , 2014, 5, 868-872.	2.8	14
50	Modulation of NMDA- and (+)TAN-67-induced nociception by GABAB receptors in the mouse spinal cord. <i>Life Sciences</i> , 2000, 68, 719-725.	4.3	13
51	Delta Opioid Receptor (DOR) Ligands and Pharmacology: Development of Indolo- and Quinolinomorphinan Derivatives Based on the Message-Address Concept. <i>Handbook of Experimental Pharmacology</i> , 2016, 247, 3-19.	1.8	13
52	Essential structure of orexin 1 receptor antagonist YNT-707, Part I: Role of the 4,5-epoxy ring for binding with orexin 1 receptor. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2017, 27, 4176-4179.	2.2	13
53	Development of Glycosylation Using the Glucopyranose 1,2-Orthobenzoate under Electrochemical Conditions. <i>Organic Letters</i> , 2013, 15, 5484-5487.	4.6	12
54	The application of a specific morphinan template to the synthesis of galanthamine. <i>Tetrahedron</i> , 2017, 73, 5751-5758.	1.9	12

#	ARTICLE	IF	CITATIONS
55	Essential structure of orexin 1 receptor antagonist YNT-707, Part II: Drastic effect of the 14-hydroxy group on the orexin 1 receptor antagonistic activity. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2018, 28, 774-777.	2.2	12
56	Syntheses of Potential Metabolites of a Potent $\mu$ -Opioid Receptor Agonist, TRK-820. <i>Chemical and Pharmaceutical Bulletin</i> , 2004, 52, 670-674.	1.3	11
57	Synthesis and assignment of the absolute stereochemistry of $\Delta^1$ -hemifistularin 3. <i>Tetrahedron</i> , 2014, 70, 6392-6397.	1.9	11
58	Administration of a delta opioid receptor agonist KNT-127 to the basolateral amygdala has robust anxiolytic-like effects in rats. <i>Psychopharmacology</i> , 2018, 235, 2947-2955.	3.1	11
59	Selective agonists of the $\delta$ -opioid receptor, KNT-127 and SNC80, act differentially on extinction learning of contextual fear memory in mice. <i>Neuropharmacology</i> , 2019, 160, 107792.	4.1	11
60	Oxidative Cleavage of the Acyl-Carbon Bond in Phenylacetone with Electrogenerated Superoxide Anions. <i>ChemElectroChem</i> , 2019, 6, 4194-4198.	3.4	11
61	Delta Opioid Receptor Agonists Ameliorate Colonic Inflammation by Modulating Immune Responses. <i>Frontiers in Immunology</i> , 2021, 12, 730706.	4.8	11
62	Synthesis of novel triplet drugs with 1,3,5-trioxazatriquinane skeletons and their pharmacologies. Part 2: Synthesis of novel triplet drugs with the epoxymethano structure (capped homotriplet). <i>Bioorganic and Medicinal Chemistry Letters</i> , 2011, 21, 6198-6202.	2.2	10
63	Synthesis of novel triplet drugs with 1,3,5-trioxazatriquinane skeletons and their pharmacologies. 1: Synthesis of triplet drugs with morphinan skeletons. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2011, 21, 4023-4026.	2.2	10
64	Synthesis of Novel Triplets with a 1,3,5-Trioxazatriquinane Skeleton and Their Pharmacologies for Opioid Receptors. <i>Archiv Der Pharmazie</i> , 2015, 348, 375-389.	4.1	10
65	Transformation of naltrexone into mesembrane and investigation of the binding properties of its intermediate derivatives to opioid receptors. <i>Bioorganic and Medicinal Chemistry</i> , 2015, 23, 439-448.	3.0	10
66	Investigation of 7-benzylidenenaltrexone derivatives as a novel structural antitrichomonal lead compound. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2015, 25, 4890-4892.	2.2	10
67	Synthesis of new opioid derivatives with a propellane skeleton and their pharmacologies: Part 5, novel pentacyclic propellane derivatives with a 6-amide side chain. <i>Bioorganic and Medicinal Chemistry</i> , 2015, 23, 6271-6279.	3.0	10
68	Lip closure training improves eating behaviors and prefrontal cortical hemodynamic activity and decreases daytime sleep in elderly persons. <i>Journal of Bodywork and Movement Therapies</i> , 2018, 22, 810-816.	1.2	10
69	Essential structure of opioid $\delta$ receptor agonist nalfurafine for binding to the $\delta$ receptor 3: Synthesis of decahydro(iminoethano)phenanthrene derivatives with an oxygen functionality at the 3-position and their pharmacologies. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2012, 22, 7711-7714.	2.2	9
70	Synthesis of a novel universal opioid receptor agonist with the 1,3,5-trioxazatriquinane skeleton and its pharmacologies. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2014, 24, 4895-4898.	2.2	9
71	A delta opioid receptor agonist, KNT-127, in the prelimbic medial prefrontal cortex attenuates glial glutamate transporter blocker-induced anxiety-like behavior in mice. <i>Journal of Pharmacological Sciences</i> , 2018, 138, 176-183.	2.5	9
72	Essential structure of orexin 1 receptor antagonist YNT-707, part III: Role of the 14-hydroxy and the 3-methoxy groups in antagonistic activity toward the orexin 1 receptor in YNT-707 derivatives lacking the 4,5-epoxy ring. <i>Bioorganic and Medicinal Chemistry</i> , 2019, 27, 1747-1758.	3.0	9

#	ARTICLE	IF	CITATIONS
73	A new NF- $\kappa$ B inhibitor based on the amino-epoxyquinol core of DHMEQ. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2010, 20, 5638-5642.	2.2	8
74	Novel Delta Opioid Receptor Agonists with Oxazatricyclodecane Structure. <i>ACS Medicinal Chemistry Letters</i> , 2014, 5, 368-372.	2.8	8
75	Asymmetric induction in cyclohexadienones carrying $\hat{\iota}$ -d-glucopyranosyl moiety. <i>Tetrahedron</i> , 2016, 72, 8428-8435.	1.9	8
76	Antitrichomonal activity of $\hat{\iota}$ opioid receptor antagonists, 7-benzylidenenaltrexone derivatives. <i>Bioorganic and Medicinal Chemistry</i> , 2017, 25, 4375-4383.	3.0	8
77	Effects of the delta opioid receptor agonist KNT-127 on electroencephalographic activity in mice. <i>Pharmacological Reports</i> , 2018, 70, 350-354.	3.3	8
78	Essential structure of orexin 1 receptor antagonist YNT-707, Part IV: The role of D-ring in 4,5-epoxymorphinan on the orexin 1 receptor antagonistic activity. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2019, 29, 2655-2658.	2.2	8
79	Anodic Oxidation of Phenols: A Key Step for the Synthesis of Natural Products. <i>Chemical Record</i> , 2021, 21, 2254-2268.	5.8	8
80	A selective delta opioid receptor agonist SNC80, but not KNT-127, induced tremor-like behaviors via hippocampal glutamatergic system in mice. <i>Brain Research</i> , 2021, 1757, 147297.	2.2	8
81	Investigation of Beckett's Case model 3: Synthesis of novel naltrexone derivatives with contracted and expanded D-rings and their pharmacology. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2010, 20, 3801-3804.	2.2	7
82	Synthesis of new opioid derivatives with a propellane skeleton and their pharmacology. Part 2: Propellane derivatives with an amide side chain. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2012, 22, 2775-2779.	2.2	7
83	Click Reaction Based on the Biosynthesis of Firefly Luciferin. <i>Chemistry Letters</i> , 2017, 46, 753-755.	1.3	7
84	Systemic administration of a delta opioid receptor agonist, KNT-127, facilitates extinction learning of fear memory in rats. <i>Journal of Pharmacological Sciences</i> , 2019, 139, 174-179.	2.5	6
85	Discovery of attenuation effect of orexin 1 receptor to aversion of nalfurafine: Synthesis and evaluation of D-nor-nalfurafine derivatives and analyses of the three active conformations of nalfurafine. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2020, 30, 127360.	2.2	6
86	Topical administration of the kappa opioid receptor agonist nalfurafine suppresses corneal neovascularization and inflammation. <i>Scientific Reports</i> , 2021, 11, 8647.	3.3	6
87	Design and synthesis of novel orexin 2 receptor agonists based on naphthalene skeleton. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2022, 59, 128530.	2.2	6
88	Discovery of orexin 2 receptor selective and dual orexin receptor agonists based on the tetralin structure: Switching of receptor selectivity by chirality on the tetralin ring. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2022, 60, 128555.	2.2	6
89	Investigation of Beckett's Case model 2: Synthesis of novel 15-16 nornaltrexone derivatives and their pharmacology. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2010, 20, 3726-3729.	2.2	5
90	Design and synthesis of novel $\hat{\iota}$ opioid receptor agonists with an azatricyclodecane skeleton for improving blood-brain barrier penetration. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2017, 27, 3495-3498.	2.2	5

#	ARTICLE	IF	CITATIONS
91	Synthesis of heterocyclic compounds with adamantane-like cage structures consisting of phosphorus, sulfur, and carbon. <i>Tetrahedron</i> , 2017, 73, 5214-5219.	1.9	5
92	Favorskii-Type Rearrangement of the 4,5-Epoxymorphinan Skeleton. <i>Organic Letters</i> , 2018, 20, 1559-1562.	4.6	5
93	Development of a luminescence-controllable firefly luciferin analogue using selective enzymatic cyclization. <i>Tetrahedron</i> , 2016, 72, 7505-7508.	1.9	4
94	Novel delta opioid receptor agonists with oxazatricyclodecane structure showing potent agonistic activities. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2017, 27, 2742-2745.	2.2	4
95	Acetic Anhydride Mediated Retro-Ene Reaction via a [4.4.3]Propellane Skeleton Intermediate Containing a Quaternary Ammonium Linkage. <i>Synthesis</i> , 2018, 50, 4263-4269.	2.3	4
96	Essential structure of orexin 1 receptor antagonist YNT-707, part V: Structure-activity relationship study of the substituents on the 17-amino group. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2020, 30, 126893.	2.2	4
97	Cold-Restraint Stress-Induced Ultrasonic Vocalization as a Novel Tool to Measure Anxiety in Mice. <i>Biological and Pharmaceutical Bulletin</i> , 2022, 45, 268-275.	1.4	4
98	Essential structure of orexin 1 receptor antagonist YNT-707: Conversion of the 16-cyclopropylmethyl group to the 16-sulfonamide group in d-nor-nalfurafine derivatives. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2022, 59, 128550.	2.2	4
99	Selective $\mu$ -Opioid Receptor Agonist, KNT-127, Facilitates Contextual Fear Extinction via Infralimbic Cortex and Amygdala in Mice. <i>Frontiers in Behavioral Neuroscience</i> , 2022, 16, 808232.	2.0	4
100	Design and synthesis of biotinylated DHMEQ for direct identification of its target NF- $\kappa$ B components. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2011, 21, 6293-6296.	2.2	3
101	Structure-Activity Relationship between Thiol Group-Trapping Ability of Morphinan Compounds with a Michael Acceptor and Anti-Plasmodium falciparum Activities. <i>Molecules</i> , 2020, 25, 1112.	3.8	3
102	Rational Drug Design of $\delta$ -Opioid Receptor Agonist TAN-67. <i>Yuki Gosei Kagaku Kyokaiishi/Journal of Synthetic Organic Chemistry</i> , 2006, 64, 371-381.	0.1	3
103	Synthesis of unnatural morphinan compounds to induce itch-like behaviors in mice: Towards the development of MRGPRX2 selective ligands. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2022, 56, 128485.	2.2	3
104	Morphinan derivatives with an oxabicyclo[3.2.1]octane structure as dual agonists toward $\mu$ and $\kappa$ opioid receptors. <i>Bioorganic and Medicinal Chemistry</i> , 2022, 53, 116552.	3.0	3
105	Effect of removal of the 14-hydroxy group on the affinity of the 4,5-epoxymorphinan derivatives for orexin and opioid receptors. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2022, 59, 128527.	2.2	2
106	Discovery of novel orexin receptor antagonists using a 1,3,5-trioxazatriquinane bearing multiple effective residues (TriMER) library. <i>European Journal of Medicinal Chemistry</i> , 2022, 240, 114505.	5.5	2
107	Glycosylation of a Newly Functionalized Orthoester Derivative. <i>Molecules</i> , 2014, 19, 2602-2611.	3.8	1
108	Novel Baeyer-Villiger-type oxidation of 4,5-epoxymorphinan derivatives. <i>Tetrahedron Letters</i> , 2021, 63, 152714.	1.4	1

#	ARTICLE	IF	CITATIONS
109	Chemistry of opioids. Preface. Topics in Current Chemistry, 2011, 299, ix-xi.	4.0	1
110	Encounter Leading to Success. Yuki Gosei Kagaku Kyokaiishi/Journal of Synthetic Organic Chemistry, 2021, 79, 162-165.	0.1	0
111	Design and Synthesis of Novel Orexin Antagonists via Structural Simplification of the Morphinan Skeleton. Heterocycles, 2021, 103, 929.	0.7	0
112	Orexin agonist improves inflammation-induced immobility. Proceedings for Annual Meeting of the Japanese Pharmacological Society, 2018, WCP2018, OR23-1.	0.0	0
113	Unique Reactions of Morphinan Skeletons and Conversions of the Skeletons to Active Alkaloids. Yuki Gosei Kagaku Kyokaiishi/Journal of Synthetic Organic Chemistry, 2018, 76, 914-921.	0.1	0
114	A Novel Rearrangement Reaction of Morphinan to Arylmorphinan Skeletons and the Pharmacologies of Arylmorphinan Derivatives. Heterocycles, 2019, 99, 134.	0.7	0